Essential Thrombocythemia Clinical Trials

Find Essential Thrombocythemia Clinical Trials Near You

A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive

Status: Recruiting
Location: See all (144) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participants have diagnosis of primary myelofibrosis (PMF) or post-polycythemia vera myelofibrosis (post-PV MF) or post-essential thrombocythemia myelofibrosis (post-ET MF) according to the International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemias 2022

• DIPSS risk category of intermediate-1, intermediate-2 or high-risk

• Spleen volume ≥ 450 cm3 by CT or MRI scan (local read sufficient if no central read available)

• Have an average TSS of ≥15 within 7 days prior to randomization, using MFSAF v. 4.0 (at least 4 out of 7 TSS assessments required for average calculation)

• Participants with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

• Blasts \<5% in peripheral blood. Assessment of blasts in peripheral blood is mandatory at screening

• Platelet count ≥ 100 x 10\^9/L in the absence of growth factors or transfusions for the previous 4 weeks

Locations
United States
Colorado
Rocky Mountain Cancer Centers
RECRUITING
Denver
Connecticut
Yale University School Of Medicine
RECRUITING
New Haven
Florida
Florida Cancer Specialist South Reg
RECRUITING
Fort Myers
The Anderson Family Cancer Institute
RECRUITING
Jupiter
Miami NS Ins Baptist Health S FL
RECRUITING
Miami
Florida Cancer Specialists-North
RECRUITING
St. Petersburg
Florida Cancer Specialists East
RECRUITING
Stuart
Georgia
Winship Cancer Institute of Emory University
RECRUITING
Atlanta
Illinois
University of Chicago Hospital
RECRUITING
Chicago
Indiana
Franciscan Health Indianapolis
RECRUITING
Indianapolis
Maryland
American Oncology Partners PA Center for Cancer and Blood Disorders
RECRUITING
Bethesda
New Jersey
Summit Medical Group Oncology
RECRUITING
Berkeley Heights
New York
New York Oncology Hematology P C
RECRUITING
Albany
Columbia University Medical Center New York Presbyterian
RECRUITING
New York
Ohio
The Ohio State University Comprehensive Cancer Center
RECRUITING
Columbus
Texas
Texas Oncology - Central South
RECRUITING
Austin
Texas Oncology PA Dallas Presbyterian Hospital
RECRUITING
Dallas
MD Anderson Cancer Center
RECRUITING
Houston
SCRI Texas Oncology Northeast Texas
RECRUITING
Tyler
Washington
Fred Hutch Cancer Research
RECRUITING
Seattle
Other Locations
Argentina
Hospital de Clinicas Jose de San Martin
RECRUITING
Buenos Aires
Hospital Italiano de Buenos Aires
RECRUITING
Caba
FUNDALEU
RECRUITING
Capital Federal
Hospital Privado de Cordoba
RECRUITING
Córdoba
Australia
Novartis Investigative Site
RECRUITING
Adelaide
Novartis Investigative Site
RECRUITING
Clayton
Austria
Novartis Investigative Site
RECRUITING
Graz
Novartis Investigative Site
RECRUITING
Salzburg
Novartis Investigative Site
RECRUITING
Sankt Pölten
Novartis Investigative Site
RECRUITING
Vienna
Belgium
Novartis Investigative Site
RECRUITING
Woluwe-saint-lambert
Brazil
Novartis Investigative Site
RECRUITING
Barretos
Novartis Investigative Site
RECRUITING
Curitiba
Grupo ELORA
RECRUITING
Florianópolis
Novartis Investigative Site
RECRUITING
Goiânia
Canada
Jewish General Hospital
RECRUITING
Montreal
China
Novartis Investigative Site
RECRUITING
Beijing
Novartis Investigative Site
RECRUITING
Changchun
Novartis Investigative Site
RECRUITING
Chongqing
Novartis Investigative Site
RECRUITING
Fuzhou
Novartis Investigative Site
RECRUITING
Guangzhou
Novartis Investigative Site
RECRUITING
Guangzhou
Novartis Investigative Site
RECRUITING
Hangzhou
Novartis Investigative Site
RECRUITING
Hefei
Novartis Investigative Site
RECRUITING
Jinan
Novartis Investigative Site
RECRUITING
Kunming
Novartis Investigative Site
RECRUITING
Nanchang
Novartis Investigative Site
RECRUITING
Nanjing
Novartis Investigative Site
RECRUITING
Nantong
Novartis Investigative Site
RECRUITING
Shanghai
Novartis Investigative Site
RECRUITING
Shenyang
Novartis Investigative Site
RECRUITING
Tianjin
Novartis Investigative Site
RECRUITING
Wenzhou
Novartis Investigative Site
RECRUITING
Wuhan
Novartis Investigative Site
RECRUITING
Wuhan
Novartis Investigative Site
RECRUITING
Yantai
France
Novartis Investigative Site
RECRUITING
Brest
Novartis Investigative Site
RECRUITING
Le Kremlin-bicêtre
Novartis Investigative Site
RECRUITING
Lens
Novartis Investigative Site
RECRUITING
Nîmes
Novartis Investigative Site
RECRUITING
Paris
Novartis Investigative Site
RECRUITING
Pessac
Novartis Investigative Site
RECRUITING
Poitiers
Novartis Investigative Site
RECRUITING
Rennes
Novartis Investigative Site
RECRUITING
Toulouse
Germany
Novartis Investigative Site
RECRUITING
Aachen
Novartis Investigative Site
RECRUITING
Cottbus
Novartis Investigative Site
RECRUITING
Erlangen
Novartis Investigative Site
RECRUITING
Hamburg
Novartis Investigative Site
RECRUITING
Mannheim
India
Novartis Investigative Site
RECRUITING
Aurangabad
Novartis Investigative Site
RECRUITING
Delhi
Novartis Investigative Site
RECRUITING
Kolkata
Novartis Investigative Site
RECRUITING
Pune
Novartis Investigative Site
RECRUITING
Rishikesh
Italy
Novartis Investigative Site
RECRUITING
Florence
Novartis Investigative Site
RECRUITING
Meldola
Novartis Investigative Site
RECRUITING
Monza
Novartis Investigative Site
RECRUITING
Novara
Novartis Investigative Site
RECRUITING
Padova
Novartis Investigative Site
RECRUITING
Palermo
Novartis Investigative Site
RECRUITING
Roma
Novartis Investigative Site
RECRUITING
Verona
Japan
Novartis Investigative Site
RECRUITING
Bunkyo Ku
Novartis Investigative Site
RECRUITING
Bunkyo-ku
Novartis Investigative Site
RECRUITING
Chūō
Novartis Investigative Site
RECRUITING
Fukuoka
Novartis Investigative Site
RECRUITING
Kamogawa
Novartis Investigative Site
RECRUITING
Kobe
Novartis Investigative Site
RECRUITING
Kumamoto
Novartis Investigative Site
RECRUITING
Kurashiki
Novartis Investigative Site
RECRUITING
Miyazaki
Novartis Investigative Site
RECRUITING
Sapporo
Novartis Investigative Site
RECRUITING
Shiwa-gun
Novartis Investigative Site
RECRUITING
Tsu
Malaysia
Novartis Investigative Site
RECRUITING
George Town
Novartis Investigative Site
RECRUITING
Johor Bahru
Novartis Investigative Site
RECRUITING
Kota Kinabalu
Novartis Investigative Site
RECRUITING
Kuala Selangor
Novartis Investigative Site
RECRUITING
Kuching
Netherlands
Novartis Investigative Site
RECRUITING
Amsterdam
Novartis Investigative Site
RECRUITING
Utrecht
Poland
Novartis Investigative Site
RECRUITING
Gdansk
Novartis Investigative Site
RECRUITING
Katowice
Novartis Investigative Site
RECRUITING
Lublin
Novartis Investigative Site
RECRUITING
Skorzewo
Novartis Investigative Site
RECRUITING
Torun
Novartis Investigative Site
RECRUITING
Wałbrzych
Novartis Investigative Site
RECRUITING
Warsaw
Republic of Korea
Novartis Investigative Site
RECRUITING
Busan
Novartis Investigative Site
RECRUITING
Jeonju
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Seoul
Novartis Investigative Site
RECRUITING
Suwon
Spain
Novartis Investigative Site
RECRUITING
Alicante
Novartis Investigative Site
RECRUITING
Barcelona
Novartis Investigative Site
RECRUITING
Donostia / San Sebastian
Novartis Investigative Site
RECRUITING
El Palmar
Novartis Investigative Site
RECRUITING
Las Palmas Gc
Novartis Investigative Site
RECRUITING
Madrid
Novartis Investigative Site
RECRUITING
Málaga
Novartis Investigative Site
RECRUITING
Pamplona
Novartis Investigative Site
RECRUITING
Salamanca
Switzerland
Novartis Investigative Site
RECRUITING
Basel
Novartis Investigative Site
RECRUITING
Bern
Novartis Investigative Site
RECRUITING
Geneva
Novartis Investigative Site
RECRUITING
Genolier
Taiwan
Novartis Investigative Site
RECRUITING
Changhua
Novartis Investigative Site
RECRUITING
Kaohsiung City
Novartis Investigative Site
RECRUITING
Tainan
Novartis Investigative Site
RECRUITING
Taipei
Turkey
Novartis Investigative Site
RECRUITING
Ankara
Novartis Investigative Site
RECRUITING
Ankara
Novartis Investigative Site
RECRUITING
Ankara
Novartis Investigative Site
RECRUITING
Bursa
Novartis Investigative Site
RECRUITING
Istanbul
Novartis Investigative Site
RECRUITING
Istanbul
Novartis Investigative Site
RECRUITING
Izmir
Novartis Investigative Site
RECRUITING
Kocaeli
Novartis Investigative Site
RECRUITING
Sakarya
Novartis Investigative Site
RECRUITING
Samsun
Contact Information
Primary
Novartis Pharmaceuticals
novartis.email@novartis.com
1-888-669-6682
Backup
Novartis Pharmaceuticals
novartis.email@novartis.com
+41613241111
Time Frame
Start Date: 2026-05-27
Estimated Completion Date: 2030-12-27
Participants
Target number of participants: 460
Treatments
Experimental: Arm 1: Pelabresib + Ruxolitinib
Participants in this arm receive pelabresib (DAK539) orally once daily for 14 days of each 21-day cycle, in combination with ruxolitinib, which is taken orally twice daily throughout each cycle. Participants may continue receiving study treatment until they experience unacceptable toxicity, disease progression, or until either the investigator or the participant decides to discontinue treatment.
Placebo_comparator: Arm 2: Placebo + Ruxolitinib
Participants in this arm receive a matching placebo orally once daily for 14 days of each 21-day cycle, together with ruxolitinib, which is also taken orally twice daily throughout each cycle.~Participants may continue receiving study treatment until they experience unacceptable toxicity, disease progression, or until either the investigator or the participant decides to discontinue treatment.
Sponsors
Leads: Novartis Pharmaceuticals

This content was sourced from clinicaltrials.gov